ReNetX Bio initiates financing round for spinal cord injury technology trial : 7 highlights

Megan Wood -   Print  |

Axerion Therapeutics rebranded as ReNetX Bio.

Here are seven highlights:


1. The company also kickstarted a Series A financing round for a Phase 1/2 clinical trial of Nogo Trap.


2. Nogo Trap is intended to treat patients with spinal cord injury.


3. Stephen Strittmatter, MD, PhD, of New Haven, Conn.-based Yale University, developed the Nogo Receptor platform technology. Dr. Strittmatter is also the founder and scientific advisor to ReNetX Bio.


4. ReNetX licensed the technology's rights.


5. The Nogo Trap is a decoy receptor binding the growth inhibitors, encouraging the body to grow nerve fibers naturally. Restoration is promoted for axonal regeneration, axonal sprouting and synaptic plasticity.


6. National Institutes of Health and the National Center for Advancing Translational Sciences are supporting the technology's development.


7. Additionally, ReNetX Bio named Erika Smith its new CEO. She is equipped with more than 25 years of experience as a life sciences investor and entrepreneur.


More articles on devices:
Tissue Regenix proposes acquisition of CellRight Technologies: 4 notes
Zimmer Biomet, Spineway, Implanet & more: 12 device company key notes
Global vertebroplasty, kyphoplasty market gains steam with boost in osteoporosis: 8 observations

© Copyright ASC COMMUNICATIONS 2021. Interested in LINKING to or REPRINTING this content? View our policies here.

Featured Webinars

Featured Whitepapers